Algae (Chlorella Sorokiniana brand name –CRYPTOMONADALES) is currently being evaluated by International Chlorella (Dr. Wang-Sponsor) for its potential as prophylaxis against avian Influenza virus H5N1 infection of humans.
Studies performed at ViroClinics B.V., Rotterdam, where ferrets were infected with different H5N1 strain (unpublished) demonstrated that the infection of ferrets with Influenza H5N1viruses can be use for the pre-clinical evaluation of countermeasures for these infections in humans.
Recently, the Sponsor has demonstrated that the green algae Chlorella Sorokiniana, contains agonists of peroxisome proliferators activated receptors (PPARs). PPARs are widely recognized as the molecular drug targets for many diseases including hyperglycemia, diabetes, obesity and cancer. Upon activation by endogenous or synthetic ligands PPAR regulate the expression of target genes involved in a variety of important physiological pathways such as lipid metabolism, insulin sensitivity, cells differentiation, inflammation, proliferation, and apoptosis. PPAR agonists have been reported to exhibit immunomodulatory effects on the activation of T cells and macrophages and the suppression of proinflammatory cytokines secretion. Futhermore, in a prelimenary report Sponsor showed an inhibitory effect on virus reflication by PPAR agonists using a rabbit model for virus-associated hemophagocytic syndrome (VAHS), a cytokine disorder in response to virus infection.
The in-life phase of the present study was conducted at ViroClinics BV, Room Ee 1989 Erasmus Medical Centre, Rotterdam, for the Sponsor. Gross Pathology and histopathology analysis was conducted by Prof. Dr. Thijs Kuiken, Department of Virology, Erasmus Medical Centre, Rotterdam, The Netherland. Virological analyses were conducted by ViroClinics BV.